Publications

5900 Results

SWOG S1602: A phase III randomized trial to evaluate BCG strain differences and priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer (NCT #03091660).

Authors
Svatek RS;Tangen CM;Meeks JJ;Gilbert SM;Lotan Y;Tyson M;Crispen P;Delacroix SE;Gills J;Daneshmand S;Woods M;Master VA;Mark JR;Alva AS;Bangs R;Nakagawa D;Unger JM;Plets M;Thompson IM;Lerner SP
Journal / Conference
ASCO GU Symposium (February 26-28, 2026); LBA629
Year
2026
Research Committee(s)
Genitourinary
Study Number(s)
S1602

A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design.

Authors
Sadeghi S;Callis S;Lara PN;Berg SA;Brown JR;Bangs R;Nakagawa D;Daneshmand S;Murchie I;Flaig TW;Petrylak DP;Lerner SP
Journal / Conference
ASCO GU Symposium (February 26-28, 2026); TPS894
Year
2026
Research Committee(s)
Genitourinary
Study Number(s)
S1937

SWOG 2427: Single arm phase II study of bladder preservation with immunoradiotherapy after a clinically meaningful response to neoadjuvant therapy in patients with muscle invasive bladder cancer (BRIGHT).

Authors
Ballas LK;Callis S;Daneshmand S;Tripathi A;Hamstra DA;Yu JB;Tyson M;Mouw KW;Meeks JJ;McConkey DJ;Rose KM;Tawagi K;Mittal K;Sachdev S;Flaig TW;Lerner SP
Journal / Conference
ASCO GU Symposium (February 26-28, 2026); TPS913
Year
2026
Research Committee(s)
Genitourinary
Study Number(s)
S2427

ASPIRE: A randomized phase III trial of androgen deprivation therapy (ADT) plus apalutamide (A) with or without docetaxel (D) in metastatic castration-sensitive prostate cancer (mCSPC) stratified by tumor suppressor gene alterations (Alliance A032302).

Authors
Kilari D;Ballman KV;Gelmann EP;Zarrabi KK;Baghaie S;Sumey CJ;Hillman DW;Bryce AH;Rose BS;Nguyen P;Montgomery RB;Berg SA;Tan A;Jacene H;Chen RC;Beltran H;Morris MJ;Galsky MD;Rosenberg JE;McKay RR
Journal / Conference
ASCO GU Symposium (February 26-28, 2026); TPS290
Year
2026
Research Committee(s)
Genitourinary

Correlation of mitophagy related genes expression and clinical outcome in metastatic colorectal cancer patients enrolled in CALGB (Alliance)/SWOG 80405.

Authors
Soni S;Yang Y;Bartolini M;Mittal P;Ou FS;Torres-Gonzalez L;Shah UH;Lo JH;Soto Trujillo S;Goretsky Y;Zhang W;Venook AP;Algaze S;Millstein J;Lenz HJ
Journal / Conference
AACR Annual Meeting 2026 (April 17-22, 2026, San Diego, CA); Abstract 1011
Year
2026
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Differences in survival outcomes among metastatic colorectal cancer patients across fibroblast growth factor receptor 2 and 3 expression levels.

Authors
Trujillo SS;Yang Y;Bartolini M;Soni S;Mittal P;Ou FS;Torres-Gonzalez L;Shah UH;Lo JH;Goretsky Y;Zhang W;Venook A;Algaze S;Millstein J;Lenz HJ
Journal / Conference
AACR Annual Meeting 2026 (April 17-22, 2026, San Diego, CA); Abstract 6751
Year
2026
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Associations of WCRF/AICR recommendations with survival and chemotherapy outcomes in colon cancer: CALGB/SWOG 80702 (Alliance).

Authors
Cheng E;Ma C;Shi Q;Shields AF;Campbell PT;Shergill AP;Guthrie KA;Couture F;Kuebler P;Kumar P;Tan B;Krishnamurthi SS;Ng K;O‘Reilly EM;Brown JC;Philip PA;Meyerhardt JA
Journal / Conference
AACR Annual Meeting 2026 (April 17-22, 2026, San Diego, CA); Abstract 5038
Year
2026
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80702

SWOG S1823/CCTG GCC-01 secondary use of data: North American patterns of care in clinical stage I germ cell tumours.

Authors
Coulombe AM;Ozgun G;Colby S;King J;Neuhouser ML;Zell JA;Arun B;Daneshmand S;Harzstark A;Arnold KB;Kollmannsberger CK;Nichols CR;Nappi L
Journal / Conference
2026 ASCO Genitourinary Cancers Symposium, San Francisco February 28, 2026; poster 622
Year
2026
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S1823

Final Results from S2302—PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (RP) versus standard of care (SOC) for participants (pts) previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC).

Authors
Reckamp KL;Redman MW;Dragnev KH;Khalil M;Henick BS;Moon J;Ahmadzai P;LeBlanc M;Carrizosa DR;Hesketh PJ;Sigal EV;Allen J;Saltos AN;Faller BA;Herbst RS;Blanke CD;Gray JE
Journal / Conference
AACR Annual Meeting 2026 (April 17-22, 2026, San Diego, CA); Abstract CT140
Year
2026
Research Committee(s)
Lung
Study Number(s)
S2302

SWOG S2414 (INSIGHT): A Randomized Phase III Trial Incorporating Pathologic Complete Response in Participants with Early-Stage Non-Small Cell Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting

Authors
Cetnar J;Zhao Y;Osarogiagbon RU;Pellini B;Boyle TA;Trejo Bittar HE;Dacic S;Hesketh PJ;Gunturu KS;Hsieh MH;Unger JM;Owen DH;Suga JM;Gelblum DY;Hirsch FR;Gray JE
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); TIP TPS8131 poster; doi: 10.1200/JCO.2026.44.16_suppl.TPS8131
Year
2026
Research Committee(s)
Lung
Study Number(s)
S2414